Introduction
While the advent of antibiotics heralded a major victory over the microbial world, at least in the form of bacteria, and has saved countless millions of lives, we have not had the same success when it comes to viruses. The nature of viruses as intracellular parasites which have evolved to be completely reliant on host cells for their replication has meant that developing virus-specific drugs represents a unique challenge. Indeed, one only has to look at the short list of currently available antivirals to realise that this is an area of need and one in which we have had only modest success. Even with the resources and effort that went into developing anti-HIV therapies we have only managed to turn this previously untreatable infection into one that is chronic and clinically manageable. It is sobering to realise that no cure for HIV appears likely in the near future.
Viruses have not had it all their own way of course. Immunisation is clearly the most successful means developed to date to combat viral infections and this has led to the complete eradication of smallpox (1) , hopefully soon to be followed by polio, although this is proving more difficult (2) . The recent introduction of the vaccine against cervical cancer, a disease caused by human papillomavirus, is the latest example of viral vaccine success with the most recent data suggesting rates of precancerous lesions are falling in target populations since its introduction (3, 4) .
However, vaccines do not exist for most viral infections. Moreover, there are situations where immunisation is either inadequate or has proven to be ineffective, or in some cases dangerous.
For example, vaccines against HIV have not been successful despite enormous efforts and resources (5) . Early RSV vaccines generated poor immune responses that not only did not prevent infection, they made subsequent infections even worse (6) . Furthermore, vaccination is ineffective for viruses that replicate actively in sites of immune privilege, such as the CNS (e.g.
Herpes virus family), or attack the immune system itself (HIV).
Anti-viral drugs, on the other hand, would potentially work in such situations but are available for only a limited number of viruses. We have highly effective anti-viral therapies against HIV which, while not curing the virus, allow it to become a clinically manageable chronic infection. Anti-influenza medications such as Tamiflu® (Oseltamivir) and Relenza® (Zanamivir) have recently been developed (7) which are useful in the acute hospital setting but are limited in general use due to the inability to rapidly identify patients with flu (rather than a range of other respiratory viruses)
and that fact that patients often present to physicians at a late stage of infection where recovery is only improved by as little as 24 hours.
While much effort has been made to develop new antivirals via natural product or small molecule screens, success has been time-consuming, fortuitous and difficult to obtain. The problem lies in the fact that viruses use much of our own cellular machinery to complete their replication cycle, making specificity a major hurdle.
Clearly new approaches are required to allow us to rapidly identify novel antiviral drug targets not only within the virus itself but also within the host cell and it is here that RNA interference offers exciting new possibilities. RNA interference, or RNAi, is a means by which one can achieve the silencing of single genes within a cell via the introduction of small double-stranded RNA molecules in the form of short-interfering RNA (siRNA) or short-hairpin RNA (shRNA) (8, 9) . RNAi was discovered in the mid1990s firstly in the plant field where Jorgensen described co-suppression or posttranslational gene silencing (10) . The mechanisms were later expanded upon and explained independently by the laboratories of Baulcombe and Waterhouse (11, 12) .
While initially thought to be limited to plants, it was soon discovered by Fire and Mello that RNAi would work in nematodes (9), a discovery for which they were awarded the Nobel Prize in 2006. The importance of RNA interference in the viral setting was quickly realised with the discovery that exogenously delivered synthetic siRNA was a powerful means to knock down viral gene expression, with HIV one of the first targets where RNAi was shown to work (13) . It offered a viral-specific therapy to limit or prevent infection. Indeed it has been speculated that the evolutionary role of RNAi was in the cellular defence against viruses and the silencing of transposable elements by the generation of virus-specific siRNA's (14) .
In this review we will outline the role of RNAi as a direct therapy against viral infections as well as cancer caused by viral infections. We will review efforts using RNAi in genome-wide knockout studies to identify previously unthought-of and novel
anti-viral drug targets that will allow the development of new classes of anti-viral drugs as well as to re-purpose some drugs currently in the clinic but for which an anti-viral use has not previously been realised.
RNAi as a therapy for viruses
RNAi is ideal for use against viruses due to viruses' dependence on a limited set of genes, high levels of replication and targets that can be non-host genes. Additionally, the development time for new siRNA is comparatively short compared to other specific drugs, such as small molecule inhibitors, meaning siRNA against newly isolated viruses or to combat siRNA resistant mutations can be rapidly developed. 
Respiratory Syncytial Virus (RSV)
Some of the earliest and most promising studies using siRNA were targeting RSV.
RSV infection is a major cause of seasonal colds, which contribute a large cost to the public health system and can be deadly to patients with compromised immune systems, such as the elderly or infants (29, 30) . With no vaccine, it is also ideal to test novel therapies such as siRNA. RSV represents the most developed study of RNAi against viruses, with the completion of a phase 2 clinical trial. The results of two animal studies were published in 2005 using different approaches to treat RSV (31, 32) . The first by Zhang et al (31) used siRNA to target the viral gene NS1 which is essential for viral replication (33) , and has been implicated in dampening host immune responses to virus (34) . In this study, RNAi was in the form of shRNAs encoded on plasmids and delivered by lipofectamine, and was shown to inhibit viral replication in cultures. When delivered intranasally by nanoparticles (TransGenex Nanobiotech Inc), viral replication and disease was limited in both prophylactic and therapeutic manners, with increased anti-viral immune responses observed. The second mouse study used siRNAs against RSV-P protein that were designed in an earlier in vitro study (35) . This study delivered siRNA intranasally before challenge with RSV and was able to show a substantial reduction in viral load and clinical symptoms in the mice (32) . There was also a therapeutic effect, as delivering siRNA up to 3 days post-infection still caused a decrease in symptoms and viral load. Most siRNA were delivered using TransIT-TKO vector, however they were surprisingly able to show naked siRNA to have comparable efficacy. Additionally the results were seen without the induction of IFN- and were not observed to inhibit a related Pneumovirus, leading to the conclusion that direct inhibition of viral genes and not immune activation was the cause for virus inhibition.
The successes of these studies led to the development by Anylam of AALN-RSV01, a 19 b.p. siRNA which targets the RSV nucleocapsid-protein gene and potently blocks RSV replication in vitro. After passing phase 1 clinical trials (36) the group extended into a phase 2 clinical trial to study the drug's efficacy (37) . The siRNA was delivered via saline inhalation with most study participants receiving multiple doses from day -1 through to +3 relative to challenge with RSV culture. While the siRNA treatment had a modest effect on reducing the total number of patients infected, it had no significant impact on viral load or any of the measured patient symptoms.
The delivery of this siRNA may be key as naked siRNA was used, possibly being trapped in the upper airways, unable to reach the viral infected cells. While naked siRNA was shown effective in mouse models (32) , the respiratory tract of humans is significantly different than rodents, who are obligate nasal breathers. Despite the very modest therapeutic effect, this study has demonstrated that nasally administered siRNA are well tolerated in humans and can have an impact on respiratory viral growth.
Hepatitis B Virus (HBV)
Despite the availability of a preventative vaccine (38) , HBV is still a very common chronic infection, with 350 million people infected worldwide, and is a leading cause of the liver cancer hepatocellular carcinoma (39) . HBV replicates almost exclusively within hepatocytes, an ideal target for siRNA therapy as liver uptake of siRNA encapsulated in liposomes or other nanoparticles is extremely high (40, 41) . Early results demonstrated that HBV replication in culture (42) or in a mouse model (43) was strongly inhibited by siRNA directed against HBV core and surface antigens, respectively. Some of the most promising anti-HBV siRNA delivery has been seen with a modified lipid know as a stable nucleic acid lipid particle (SNALP), which has a longer half-life in serum than normal lipids and is specifically designed to deliver siRNA to the liver (44) . Using siRNA that were modified to improve in vivo stability (45) and encapsulated in SNALPs, the group administered therapy i.v. in a mouse model of HBV (45) . The results were highly promising, with multiple doses able to induce a >1 log reduction in circulating HBV DNA. Long term reduction in viral titres out to 7 days were observed following a single treatment, and the group was also able to maintain viral suppression when dosing mice weekly with siRNA. The modified siRNA were also shown to have an improved toxicity profile and did not induce immune responses when tested against unmodified siRNA. Stable delivery of shRNA by adeno-associated viruses has been proposed as an alternative delivery and has been shown to be safe and effective at reducing HBV viral load in vivo (46, 47) . While these vectors may achieve more stable gene knockdown, safety concerns compared to non-viral vectors may limit their clinical use. All the aforementioned studies used HBVsAg as a target. Overall, siRNA against HBV seems an attractive approach, however clinical development has been slow, with only a phase I trial conducted to date (48) . In this trail plasmid encoded shRNA against 4 different HBV subtypes was able to be delivered to patients safely however to only modest effect against HBV and evidence of an anti siRNA immune response.
Targeting human genes to limit viral replication
Targeting human genes is an attractive option when viruses have high rates of mutations so can quickly develop resistance against siRNA. While care is required when targeting host genes as to not disrupt any critical normal functions, this field is blossoming due to recent successes at siRNA inhibition of HIV and HCV, two of the most serious chronic viral infections.
Hepatitis C virus (HCV)
The development of siRNA for HCV is one of the most novel in the antiviral field. Like HBV, HCV is a chronic viral infection of the liver, with an estimated 200 million people infected worldwide and an increasing cause of hepatocellular carcinoma (49) .
HCV has a very complicated lifecycle and the discovery of microRNA uncovered a novel host target to inhibit viral replication. Early gene expression studies showed a high level of expression of the microRNA, mir-122, in the liver (50) , and this was implicated in lipid metabolism and cholesterol production (51, 52 In studies in chronically infected chimpanzees, dosing of 1 mg/kg or 5 mg/kg showed a large reduction in HCV viral titres which remained low following drug withdrawal (55) . Cholesterol levels were also reduced in the animals, suggesting specific mir-122 inhibition was being observed, and miravisen was well tolerated in all groups. HIV polymerase (66) . To deliver this lentiviral construct, the group took advantage of a haematopeitic stem cell transplantation that was being undertaken to treat patients for AIDS related lymphoma (67) . In this setting patients receive bone marrow transplantations, often of their own cryopreseved CD34+ stem cells, after whole body irradiation to eradicate the lymphoma. A tiny proportion (0.2%) of cells were transduced with the lentiviral construct due to safety concerns about the impact of the lentivirus on normal cell function, meaning the impact of the therapy on viral replication was unable to be assessed. However, the group was able to demonstrate long term engraftment and expression of the lentivirus in both bone marrow progenitors and blood T-cells, B-cells, and macrophages up to 2 years after engraftment, demonstrating the feasibility of the procedure to safely block viral replication. While a bone marrow transplant is a dangerous and costly procedure, the ability to perform the therapy with a patient's own cells and potential for a cure to HIV means lentiviral delivered shRNA therapy is one of the most promising for AIDS treatment.
Immune activation by siRNA
While overlooked in early studies, it is now well established that siRNA can activate innate immune responses through detection via pattern recognition receptors and lead to production of type 1 interferons IFN- and IFN- (68, 69). Given IFNs' natural antiviral activity, the concept of using this feature of siRNAs to bolster these effects has been explored by several groups including our own. While it has been shown that siRNAs can be modified to activate receptors such as Rig-1 (70) or TLR-9 (71), siRNA is normally recognised by TLR-7 in mice and TLR-7 and 8 in humans (69) .
The recognition of TLRs by siRNA is sequence specific, with certain sequences such as those which are uridine-rich shown to induce higher responses (72) . Interestingly, some viruses are exquisitely sensitive to IFN-, casting doubts on results from early studies using siRNA against viruses. Indeed it was recently shown that modification of siRNA to remove immune stimulation while retaining gene silencing ability removed both in vivo and in vitro effects of an siRNA against influenza A (73). The development of modifications such as the addition of 2'O-methly groups or 2'-fluoro groups to the antisense strand to remove immune activating ability has allowed silencing effects to be separated from immune effects (45) .
While an important consideration in interpreting experimental results using siRNA, the efficacy of immune activating siRNA, however, may result in improved antiviral therapy compared to non immune activating siRNA. The addition of immune activation to siRNA has been shown to improve siRNA potency against of influenza A, and human papilloma virus (17, 74) . As many viruses also dampen interferon- responses to aid in their survival (75, 76) , using siRNA to reactivate these responses is likely to assist viral eradication. Like any drug that manipulates the immune system, great care when testing and anticipation of any impact on patient immune system are required when testing siRNA in humans. We have undertaken such a screen using the kinome RNAi subset, that is all the genes that encode for kinases, in order to define new human papillomavirus susceptibility genes. Here we will review and discuss RNAi screening efforts to date.
RNAi Screening to Identify Novel Antiviral Targets

Screening Technologies
The concept of the RNAi screen is rather simple -seed cells and transfect them with There are many factors involved in developing a successful screen and these will vary depending on the platform of choice, readout assay and RNAi library chosen.
In terms of the screen itself there are three important steps (Figure 2 ). There are have been several recent genome-wide RNAi screens published that have identified novel host factors required for viral replication which we review below. gene to read out viral production. The screen was performed using siRNAs targeting 21,121 genes. Pools were classified a hit if the activity of the p24 or ß-Gal was reduced by more than or equal to two standard deviations (SD) from the plate mean.
Human immunodeficiency virus (HIV)
Another criterion for hit validation was that siRNA should not decrease cell viability by more than two SD. From this, 386 pools met these criteria and were further validated using the four-pooled siRNA in a separated format, resulting in 273 genes identified. Zhou et al used a similar strategy and found 232 genes play some role in HIV replication. Interestingly, only fifteen genes in common were found between these two studies, with seven previously known to be involved in HIV replication including CD4 and CXCR4 (106) . A third screen identified 295 genes that also had limited overlap with each of the previous two studies (108) .
This lack of overlap appears to be a common theme in RNAi screens and may result from many factors. A meta-analysis looking at the lack of overlap between these three siRNA screens attributed the lack of overlap to experimental noise, differences in sampling time, and variations in hit selection criteria (109) . They further calculated that there was only a 50% chance of the top 300 top hits being obtained in an exactly repeated screen.
A more robust study using Jurkat human T-cells and a lentiviral -shRNA system targeted to 54,509 transcripts was recently undertaken using an endpoint assay of inhibition of virus replication as a readout (110) . Of the 54,509 transcripts, only Once again these three RNAi genome-wide screens only had 32 genes in common.
West Nile Virus (WNV)
WNV is a member of the Flaviviridae 
Hepatitis C Virus (HCV)
To date, there is a lack of selective antiviral therapy or preventive vaccine against HCV and much hope has been placed in genome-wide RNAi screens to identify host factors that are essential for HCV lifecycle. Tai et al identified 96 cellular host factor proteins that are required for HCV replication, with a remarkable number of these factors being implicated in vesicle organization and biogenesis (114) . Among the identified genes, phosphatidylinositol 4-kinase (PI4KA) and COPI vesicle coat complex were tested against some selective small molecule inhibitors. The outcome revealed the inhibition of HCV growth confirming the importance of these host factors for viral replication.
Human papillomavirus (HPV)
Here at the AID we have undertaken an RNAI screen targeting HPV. HPV is a double-stranded small DNA virus. The virus is subcategorized into two main serotypes, high-risk HPV (HR-HPV) and low-risk HPV (LR-HPV). The HR-HPV is responsible for approximately 99.7% of cervical cancer cases among women. In our laboratory an siRNA-based screen was carried out on 779 genes from the kinome 
Conclusions of siRNA therapy for viruses
While siRNA has been long proposed as an excellent clinical tool, early difficulties in delivery has prevented it from reaching its potential. However, with the results of several clinical trials that supposedly demonstrate its effectiveness resulting in less than optimal outcomes, the field awaits true success. Most issues centre around solving the delivery problem. Genome-wide RNAi screening has identified a whole new range of host cell factors currently under investigation. While the screen process itself needs to be carefully worked out and controlled, results are promising ,with many new targets already having small molecule inhibitors ready to use in the clinic.
